

Susanna B Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7285202/publications.pdf>

Version: 2024-02-01

92
papers

3,908
citations

172443
29
h-index

128286
60
g-index

92
all docs

92
docs citations

92
times ranked

4445
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , 2023, 17, 222-236.	2.9	20
2	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 223-232.	2.9	16
3	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 65-76.	2.8	11
4	Mechanisms, Mediators, and Moderators of the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy. <i>Cancers</i> , 2022, 14, 1224.	3.7	20
5	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103575.	4.4	18
6	Differences in nerve excitability properties across upper limb sensory and motor axons. <i>Clinical Neurophysiology</i> , 2022, 136, 138-149.	1.5	2
7	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2022, 30, 5965-5974.	2.2	2
8	Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. <i>BMJ Open</i> , 2022, 12, e057950.	1.9	1
9	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> , 2022, 31, 3091-3107.	3.1	11
10	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. <i>Supportive Care in Cancer</i> , 2021, 29, 1103-1110.	2.2	12
11	A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. <i>Scientific Reports</i> , 2021, 11, 1786.	3.3	10
12	A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy. <i>Translational Vision Science and Technology</i> , 2021, 10, 24.	2.2	15
13	Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100420.	1.7	8
14	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , 2021, 4, e2036695.	5.9	49
15	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. <i>Oncologist</i> , 2021, 26, 366-374.	3.7	12
16	A Versatile Fluorescent Sensor Array for Platinum Anticancer Drug Detection in Biological Fluids. <i>ACS Sensors</i> , 2021, 6, 1261-1269.	7.8	20
17	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. <i>Supportive Care in Cancer</i> , 2021, 29, 6379-6387.	2.2	4
18	Effect of exercise on neuromuscular toxicity in oxaliplatin-treated mice. <i>Muscle and Nerve</i> , 2021, 64, 225-234.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.1	16
20	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , 2021, 21, 221-237.	4.4	7
21	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 821-828.	4.9	24
22	Chemotherapy and peripheral neuropathy. <i>Neurological Sciences</i> , 2021, 42, 4109-4121.	1.9	21
23	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021, 99, 102241.	7.7	29
24	Systematic Review of Exercise for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. , 2021, , 183-241.		6
25	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.	3.3	11
26	Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , 2020, 131, 308-323.	1.5	63
27	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , 2020, 21, 44-58.	1.4	22
28	Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. <i>Hematological Oncology</i> , 2020, 38, 229-243.	1.7	28
29	Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. <i>Clinical Neurophysiology</i> , 2020, 131, 783-790.	1.5	5
30	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1005-1016.	2.8	16
31	Peripheral nerve maturation and excitability properties from early childhood: Comparison of motor and sensory nerves. <i>Clinical Neurophysiology</i> , 2020, 131, 2452-2459.	1.5	3
32	Isaacs syndrome: the frontier of neurology, psychiatry, immunology and cancer. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1243-1244.	1.9	13
33	Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , 2020, 124, 232-244.	1.8	9
34	Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. <i>Supportive Care in Cancer</i> , 2020, 28, 4459-4466.	2.2	19
35	Peripheral neuropathy in hematologic malignancies “ Past, present and future. <i>Blood Reviews</i> , 2020, 43, 100653.	5.7	16
36	The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , 2020, 18, 403-417.	4.4	13

#	ARTICLE	IF	CITATIONS
37	Electrophysiological and phenotypic profiles of taxane-induced neuropathy. <i>Clinical Neurophysiology</i> , 2020, 131, 1979-1985.	1.5	14
38	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1023-1032.	1.2	21
39	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	1.9	43
40	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 360-361.	3.1	4
41	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	3.1	11
42	Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S40-S51.	3.1	33
43	The Toxic Neuropathy Consortium of the Peripheral Nerve Society. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S4-S5.	3.1	3
44	Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S13-S25.	3.1	34
45	Amyotrophic lateral sclerosis diagnostic index. <i>Neurology</i> , 2019, 92, e536-e547.	1.1	17
46	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , 2019, 13, 495-502.	2.9	14
47	Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.	2.2	30
48	Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 3849-3857.	2.2	56
49	009...Axonal excitability properties in dravet's syndrome reflect effect of loss of sodium channels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A4.1-A4.	1.9	0
50	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 949-955.	4.9	27
51	Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2018, 129, 974-980.	1.5	15
52	Oxaliplatin and neuropathy: A role for sodium channels. <i>Clinical Neurophysiology</i> , 2018, 129, 670-671.	1.5	6
53	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , 2018, 57, 615-621.	2.2	2
54	Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. <i>Muscle and Nerve</i> , 2018, 57, 848-851.	2.2	37

#	ARTICLE	IF	CITATIONS
55	Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer. JAMA Neurology, 2018, 75, 980.	9.0	73
56	Inflammatory neuropathies: all shapes and sizes. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1128-1128.	1.9	1
57	Comparison of cross-sectional areas and distal-proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 777-783.	2.2	27
58	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	1.5	15
59	004â€...Mechanisms of nerve dysfunction in inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A3.1-A3.	1.9	0
60	Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483.	1.9	93
61	Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. European Journal of Cancer, 2017, 73, 22-29.	2.8	130
62	Too fast: rare neuropathic pain state associated with easy activation of NaV1.9. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 194-194.	1.9	0
63	Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 2017, 264, 882-890.	3.6	23
64	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175.	1.5	50
65	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493.	2.2	59
66	Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 2017, 81, 355-368.	5.3	157
67	Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 721-725.	2.2	8
68	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 2017, 128, 2022-2028.	1.5	25
69	Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 2017, 55, 424-427.	2.2	10
70	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. PLoS ONE, 2017, 12, e0170814.	2.5	177
71	Fast-adapting mechanoreceptors are important for force control in precision grip but not for sensorimotor memory. Journal of Neurophysiology, 2016, 115, 3156-3161.	1.8	9
72	Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treatment Reviews, 2016, 50, 118-128.	7.7	69

#	ARTICLE	IF	CITATIONS
73	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.1	76
74	Acute bulbar, neck and limb weakness with monospecific anti-IGF1a antibody: A rare localized subtype of Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2016, 53, 143-146.	2.2	2
75	Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. <i>Clinical Neurophysiology</i> , 2016, 127, 2355-2361.	1.5	33
76	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. <i>EBioMedicine</i> , 2015, 2, 1916-1922.	6.1	25
77	Reply: Biomarkers of "acute-onset" chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2015, 138, e336-e336.	7.6	0
78	Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 973-985.	1.9	320
79	Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2014, 137, 2155-2163.	7.6	35
80	Axonal dysfunction with voltage gated potassium channel complex antibodies. <i>Experimental Neurology</i> , 2014, 261, 337-342.	4.1	14
81	Chemotherapy-induced peripheral neurotoxicity: A critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 419-437.	329.8	547
82	Impact of oxaliplatin-induced neuropathy: a patient perspective. <i>Supportive Care in Cancer</i> , 2012, 20, 2959-2967.	2.2	93
83	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1189-1190.	2.3	2
84	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , 2011, 43, 367-374.	2.2	69
85	Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. <i>Archives of Neurology</i> , 2011, 68, 862.	4.5	63
86	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.	3.7	171
87	Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. <i>Brain</i> , 2011, 134, 3185-3197.	7.6	35
88	Dose Effects of Oxaliplatin on Persistent and Transient Na ⁺ Conductances and the Development of Neurotoxicity. <i>PLoS ONE</i> , 2011, 6, e18469.	2.5	61
89	Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. <i>Oncology</i> , 2009, 77, 342-348.	1.9	21
90	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.	1.6	153

#	ARTICLE	IF	CITATIONS
91	Axonal ion channels from bench to bedside: A translational neuroscience perspective. Progress in Neurobiology, 2009, 89, 288-313.	5.7	144
92	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 2009, 132, 2712-2723.	7.6	198